Skip to content

Interest in receiving psychedelic-assisted therapy among marginalized women: Implications and findings from a community-based study in Canada.

Elena Argento, Shira Goldenberg, Kathleen Deering, Jennifer Lavalley, Melissa Braschel, Brittany Bingham, Kate Shannon

Drug and Alcohol Dependence Reports March 16, 2022 DOI: 10.1016/j.dadr.2022.100044 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Observational cohort Peer reviewed
Sample size 486
Population Marginalized women in Metro Vancouver, Canada, aged 20-67 years, over half identifying as Indigenous (First Nations, Metis or Inuit)
Topics Psychedelic-assisted therapy
Keywords Psychedelic care Entheogenic therapy Psychedelic treatment Mental well-being Psychological health Mental healthcare Mental health support Mental health solutions Marginalized women Vulnerable populations Underserved communities Women with trauma At-risk women Specific populations Trauma-informed therapy Trauma treatment Trauma support Healing from trauma Complex trauma Healthcare access Accessible care Demand for care Unmet healthcare needs Equitable access Care accessibility
Citations 6
Key findings Among 486 marginalized women, 43% were interested in receiving psychedelic-assisted therapy. Interest was independently associated with daily crystal methamphetamine use in the last six months (AOR 3.02), lifetime mental health conditions (AOR 2.13), childhood abuse (AOR 1.99), lifetime psychedelic use (AOR 1.97), and younger age (AOR 0.97 per year older). The authors argue that extending psychedelic medicine to marginalized women should integrate trauma-informed care and broader socio-structural supports.

Abstract

Background: Psychedelic-assisted therapies are receiving mounting attention for their therapeutic potential. However, little is known about interest among women who experience elevated risk of mental health and substance use disorders. This study examined interest in receiving psychedelic-assisted therapy and socio-structural factors associated with interest among marginalized women.

Methods: Data (2016-2017) were drawn from two community-based, prospective open cohorts of >1000 marginalized women in Metro Vancouver, Canada. Bivariate and multivariable logistic regression examined associations with interest in receiving psychedelic-assisted therapy. Among women who used psychedelics, additional data were collected to describe ratings of personal meaningfulness, sense of wellbeing, and spiritual significance.

Results: Of 486 eligible participants (aged 20-67 years), 43% (n = 211) were interested in receiving psychedelic-assisted therapy. Over half identified as Indigenous (First Nations, Métis or Inuit). Factors independently associated with interest in psychedelic-assisted therapy in multivariable analysis included: daily crystal methamphetamine use in the last six months (Adjusted Odds Ratio [AOR] 3.02; 95%Confidence Interval (CI) 1.37-6.65), lifetime mental health conditions (depression, anxiety, post-traumatic stress disorder) (AOR 2.13; 95%CI 1.27-3.59), childhood abuse (AOR 1.99; 95%CI 1.02-3.88), lifetime psychedelic use (AOR 1.97; 95%CI 1.14-3.38), and younger age (AOR 0.97 per year older; 95%CI 0.95-0.99).

Conclusions: Several mental health and substance use-related variables that have been demonstrated to be amenable to psychedelic-assisted therapy were associated with interest in receiving psychedelic-assisted therapy among women in this setting. As access to psychedelic-assisted therapies continues to expand, any future approaches to extend psychedelic medicine to marginalized women should integrate trauma-informed care and broader socio-structural supports.

Comparable studies

Other observational and cohort studies on psychedelic-assisted therapy, most cited first.

Study Year Design Participants
Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy Patients in a private practice setting 2019 Observational study n = 235
MDMA-Assisted Psychotherapy Using Low Doses in a Small Sample of Women with Chronic Posttraumatic Stress Disorder Women with chronic PTSD secondary to sexual assault 2008 Observational cohort n = 6
The Peak Experience Variable in DPT-Assisted Psychotherapy with Cancer Patients Cancer patients 1977 Observational study n = 128
Acute subjective effects in LSD- and MDMA-assisted psychotherapy Patients with psychiatric disorders (posttraumatic stress disorder and major... 2020 Observational study n = 18
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample. Individuals with depressive symptoms planning a psychedelic experience in naturalistic... 2022 Observational cohort n = 302

Citations in the library

Explore topics